期刊文献+

514例体检者生化指标与中医痰证的相关性分析 被引量:15

Relationship study between clinical biochemistry parameters and TCM phlegm syndrome in a population of 514 cases undergoing health check-up
原文传递
导出
摘要 目的:从常用的血液生化检测指标中探索痰证病理的共性指标。方法:对1 134名参加健康体检的体检者,运用证素辨证法得出各证素积分,228例"痰"证素积分≥70分者归为痰证组,286名所有证素积分均<70分者归为健康对照组。采用单因素协方差分析,校正年龄和性别因素的影响后,比较两组的生化全套各项指标的差异。结果:痰证组中,体质量、体质指数、丙氨酸氨基转移酶和谷酰转肽酶高于对照组(P<0.05),载脂蛋白A1和高密度脂蛋白水平均低于对照组(P<0.01,P<0.05)。结论:痰证组与对照组的差异均为营养物质代谢相关的指标,提示代谢异常是"痰"主要病理基础之一。载脂蛋白A1等差异指标可作为"痰"证病理的潜在共性指标进一步研究。 Objective: To explore the common markers of phlegm syndrome from blood biochemistry parameters. Methods: The syndrome dement differentiation was conducted based on TCM diagnosis information collected from the people undergoing TCM health check-up. The phlegm group was consisting of 228 people with the score of accumulated phlegm points larger than 70, while 286 people with scores of all TCM syndromes less than 70 were grouped as the controls. Differences in biochemistry parameters between phlegm and control groups were tested and adjusted by sex and age using the analysis of covariance. Results: In the phlegm group, body weight, BMI, alanine transaminase (ALT) and gamma glutamyl transpeptidase (GGT) raised (P〈0.05), however the levels of apolipoprotein A1 (ApoA1) and high-density lipoprotein (HDL) declined (P〈0.01, P〈0.05). Conclusion: Metabolic disorders are supposed to be involved in the pathology of TCM phlegm syndrome since all discrepancies are the parameters related to metabolism. Weight, BMI, ALT, GGT, ApoA1 and HDL might possibly be considered as the common markers to phlegm syndrome and wortb further study.
出处 《中华中医药杂志》 CAS CSCD 北大核心 2013年第7期2078-2080,共3页 China Journal of Traditional Chinese Medicine and Pharmacy
基金 国家重点基础研究发展计划(973计划)(No.2011CB505405) 福建省社会发展科技重大项目(No.2010Y4005) 福建省教育厅重点课题(No.JA12166)~~
关键词 痰证 共性指标 代谢异常 生化检查 Phlegm syndrome Common parameter Metabolic disorders Clinical biochemistry
  • 相关文献

参考文献9

  • 1朱文锋著..证素辨证学[M].北京:人民卫生出版社,2008:319.
  • 2朱文锋.中医主症鉴别诊断学[M].长沙:湖南科技出版社,2000.316-331. 被引量:21
  • 3中华人民共和国卫生部.中药新药临床研究指导原则[M].北京:中华人民共和国卫生部,1993.8-74. 被引量:222
  • 4张鹏,刘鹏,贺劲,徐伟建,毕力夫,王伟.冠心病病人血脂改变与中医证型关系的临床研究[J].中西医结合心脑血管病杂志,2010,8(12):1428-1430. 被引量:34
  • 5娄彦梅,李峰,霍艳明,王玉光,倪量.原发性高脂血症中医证型与客观指标相关性研究[J].中华中医药杂志,2010,25(4):631-633. 被引量:26
  • 6Ghouri N,Preiss D,Sattar N.Liver enzymes,nonalcoholic fatty liver disease,and incident cardiovascular disease:a narrative review and clinical perspective of prospective data.Hepatology, 2010,52(3):1156-1161. 被引量:1
  • 7Bonnet F,Ducluzeau P,Gastaldelli A.Liver enzymes are associated with hepatic insulin resistance,insulin secretion,and glucagon concentration in healthy men and women.Diabetes,2011, 60(6):1660-1667. 被引量:1
  • 8Uetani E, Tabara Y, Igase M, et al. Liver enzyme and adipocytokine profiles are synergistically associated with insulin resistance: the J-SHIPP Study. J Atheroscler Thromb,2012 May:12. 被引量:1
  • 9Mistry D, Stockley R A. Gamma-glutamyhransferase: the silent partner? COPD,2010,7(4):285-290. 被引量:1

二级参考文献24

共引文献298

同被引文献222

引证文献15

二级引证文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部